Incyte Corporation (NASDAQ:INCY) had its price target boosted by research analysts at BMO Capital Markets from $162.00 to $166.00 in a research note issued on Tuesday. BMO Capital Markets’ target price would indicate a potential upside of 46.58% from the company’s current price.

Several other analysts have also recently commented on INCY. Oppenheimer Holdings, Inc. reissued a “hold” rating and issued a $135.00 price target on shares of Incyte Corporation in a report on Thursday, August 31st. J P Morgan Chase & Co reissued a “buy” rating and issued a $149.00 price target on shares of Incyte Corporation in a report on Thursday, August 31st. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 price target on shares of Incyte Corporation in a report on Thursday, July 27th. Credit Suisse Group set a $152.00 price target on Incyte Corporation and gave the company a “buy” rating in a report on Sunday, July 16th. Finally, Raymond James Financial, Inc. raised Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price target for the company in a report on Monday, September 11th. Seven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $144.98.

Incyte Corporation (INCY) traded down 0.87% during mid-day trading on Tuesday, hitting $113.25. The stock had a trading volume of 2,170,902 shares. The stock has a 50-day moving average price of $115.21 and a 200 day moving average price of $124.22. The firm’s market cap is $23.30 billion. Incyte Corporation has a 12-month low of $83.01 and a 12-month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The company had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. During the same period last year, the firm earned $0.19 EPS. The firm’s revenue for the quarter was up 41.6% on a year-over-year basis. Equities analysts anticipate that Incyte Corporation will post ($0.82) EPS for the current fiscal year.

WARNING: “Incyte Corporation (INCY) PT Raised to $166.00” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/31/incyte-corporation-incy-pt-raised-to-166-00.html.

In other Incyte Corporation news, President Herve Hoppenot sold 70,502 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total transaction of $8,421,463.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 100,000 shares of the company’s stock in a transaction on Friday, September 8th. The shares were bought at an average cost of $132.00 per share, with a total value of $13,200,000.00. The disclosure for this purchase can be found here. Insiders have sold 101,147 shares of company stock valued at $12,615,101 in the last three months. 17.70% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. D. Scott Neal Inc. purchased a new position in Incyte Corporation during the second quarter worth $103,000. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Incyte Corporation in the second quarter valued at $104,000. Acrospire Investment Management LLC grew its position in shares of Incyte Corporation by 18.2% in the second quarter. Acrospire Investment Management LLC now owns 1,300 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 200 shares during the period. Tower Research Capital LLC TRC purchased a new stake in shares of Incyte Corporation in the first quarter valued at $105,000. Finally, Cornerstone Advisors Inc. grew its position in shares of Incyte Corporation by 19.6% in the second quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 145 shares during the period. 88.85% of the stock is owned by institutional investors.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.